Abstract
Streptomyces spp. are robust producers of medicinally-, industrially- and agriculturally-important small molecules. Increased resistance to antibacterial agents and the lack of new antibiotics in the pipeline have led to a renaissance in natural product discovery. This endeavor has benefited from inexpensive high quality DNA sequencing technology, which has generated more than 140 genome sequences for taxonomic type strains and environmental Streptomyces spp. isolates. Many of the sequenced streptomycetes belong to the same species. For instance, Streptomyces albus has been isolated from diverse environmental niches and seven strains have been sequenced, consequently this species has been sequenced more than any other streptomycete, allowing valuable analyses of strain-level diversity in secondary metabolism. Bioinformatics analyses identified a total of 48 unique biosynthetic gene clusters harboured by Streptomyces albus strains. Eighteen of these gene clusters specify the core secondary metabolome of the species. Fourteen of the gene clusters are contained by one or more strain and are considered auxiliary, while 16 of the gene clusters encode the production of putative strain-specific secondary metabolites. Analysis of Streptomyces albus strains suggests that each strain of a Streptomyces species likely harbours at least one strain-specific biosynthetic gene cluster. Importantly, this implies that deep sequencing of a species will not exhaust gene cluster diversity and will continue to yield novelty.
Highlights
More than two-thirds of all therapeutic small molecules used in medicine are derived or inspired from complex natural products produced by filamentous actinobacteria, most notably Streptomyces spp
Strain-Level Diversity of Secondary Metabolism in Streptomyces albus phylogeny was reconstructed in order to infer a taxonomic relationship among sequenced Streptomyces spp. and assess redundancy in the genomic database
The putative biosynthetic capabilities of six S. albus strains were analysed here, which identified a core secondary metabolome specified by 18 biosynthetic gene clusters as well as 14 auxiliary gene clusters and 16 strain-specific gene clusters
Summary
More than two-thirds of all therapeutic small molecules used in medicine are derived or inspired from complex natural products produced by filamentous actinobacteria, most notably Streptomyces spp. [1]. More than two-thirds of all therapeutic small molecules used in medicine are derived or inspired from complex natural products produced by filamentous actinobacteria, most notably Streptomyces spp. Streptomyces spp. are predominantly known as filamentous soil bacteria that have a differentiating mycelial life-cycle, which begins with spore germination and outgrowth of a vegetative mycelium and ends with production of reproductive aerial hyphae and the formation of unigenomic spores [2]. Aerial hyphae production and sporulation is often accompanied by the production of secondary metabolites. These secondary metabolites are most likely used to outcompete neighbouring organisms [3]. Biotechnology has exploited many of PLOS ONE | DOI:10.1371/journal.pone.0116457. Biotechnology has exploited many of PLOS ONE | DOI:10.1371/journal.pone.0116457 January 30, 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
